loading page

Impact of chronic kidney disease on in-hospital mortality and clinical outcomes of catheter ablation of ventricular tachycardia: Insights from the national readmission database
  • +7
  • Mahmoud Khalil,
  • Ahmed Maraey,
  • Amro Aglan,
  • Emmanuel akintoye,
  • Mahmoud Salem,
  • Ahmed Elzanaty,
  • Ahmed Younes,
  • Ayman Saeyeldin,
  • Chirag Barbhaiaya,
  • Mohamed Shokr
Mahmoud Khalil
Lincoln Medical and Mental Health Center
Author Profile
Ahmed Maraey
North Dakota University System
Author Profile
Amro Aglan
Lahey Hospital and Medical Center
Author Profile
Emmanuel akintoye
Cleveland Clinic Foundation
Author Profile
Mahmoud Salem
Baylor Health Care System
Author Profile
Ahmed Elzanaty
University of Toledo College of Medicine
Author Profile
Ahmed Younes
East Carolina University
Author Profile
Ayman Saeyeldin
Saint Mary's Hospital Finkelstein Health Sciences Library
Author Profile
Chirag Barbhaiaya
New York University Medical Center
Author Profile
Mohamed Shokr
New York University Medical Center
Author Profile

Abstract

Background: Catheter ablation is an effective treatment for ventricular tachycardia (VT), albeit the decision to undergo this procedure is often influenced by underlying comorbidities. The present study aims at evaluating the effects of chronic kidney disease (CKD) on clinical outcomes of VT ablation. Methods: We identified 7,212 patients who presented between 2016-2018 and underwent catheter ablation for VT. Their clinical data were retrospectively accrued from the national readmission database (NRD) using the corresponding diagnosis codes. We compared clinical outcomes between patients with chronic kidney disease (CKD-group) and patients without. Odds ratios (OR) for the primary and secondary outcomes were calculated, and multivariable regression analysis was utilized to adjust for confounding variables. Results: Compared with patients without CKD, patients in CKD-group were older (mean age 67.9 vs. 60.5 years, P <0.01), had a longer mean length of stay (8.73 vs. 5.69 days, P <0.01), and higher in-hospital mortality (OR 2.24, 95% confidence interval (CI) (1.29-3.88), P<0.01). CKD-group patients had increased risk of developing acute kidney injury (10% vs. 8.6%, P<0.01) and 30-day readmission rate due to VT (OR 1.77, 95% CI (1.17-2.69), P<0.01). Conclusion: In patients with CKD, VT ablation is associated with worse clinical outcomes in-hospital mortality and 30-day readmission rate. This significantly influences the decision-making prior to performing this procedure.